Michelle Sariev
Family · Atlanta, GANPI 1902168610
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Gilead accounts for 73.0% of it on its own, with 32 other manufacturers making up the rest. 2025 is the largest year on record at $13,516, more than ten times the $708 reported in 2021. Among family clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 290 payments — averaging $60.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$13K
- Viiv Healthcare Company$2K
- Merck$493
- Novo Nordisk$286
- Theratechnologies Inc.$261
- EMD Serono, Inc.$236
- plus $2K from 27 others
What the payments were for
- Speaking & faculty fees$10,01057%
- Travel & lodging$1,0886%
- Food & beverage$6,25936%
- Education$1881%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 66 | $12,817 |
| Viiv Healthcare Company | 89 | $1,807 |
| Merck | 23 | $493 |
| Novo Nordisk | 16 | $286 |
| Theratechnologies Inc. | 10 | $261 |
| EMD Serono, Inc. | 12 | $236 |
| Lilly USA, LLC | 10 | $175 |
| Janssen Products, LP | 2 | $173 |
| AbbVie | 9 | $168 |
| Boston Scientific | 2 | $151 |
| Johnson & Johnson(2 entities) | 8 | $129 |
| Verity Pharmaceuticals Inc. | 5 | $83 |
| Pfizer | 3 | $71 |
| Janssen Scientific Affairs, LLC | 1 | $68 |
| Exact Sciences | 4 | $65 |
| Esperion Therapeutics, Inc. | 4 | $54 |
| Kowa Pharmaceuticals America, Inc. | 4 | $48 |
| Acerus Pharmaceuticals Corporation | 2 | $45 |
| Dexcom, Inc. | 2 | $44 |
| Paratek Pharmaceuticals, Inc. | 2 | $44 |
| GSK | 2 | $37 |
| Napo Pharmaceuticals Inc | 2 | $34 |
| Tolmar, Inc. | 2 | $32 |
| Astellas Pharma US Inc | 1 | $27 |
| Hologic Sales And Service, LLC | 1 | $26 |
| Tandem Diabetes Care, Inc. | 1 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $25 |
| Sanofi Pasteur Inc. | 1 | $22 |
| Abbott | 1 | $22 |
| AstraZeneca | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Antares Pharma, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,545 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 13 | $51,756 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 11 | $39,855 |
| Testosterone Cypionate | 22 | $1,174 |
| Estradiol | 32 | $504 |
| ProgesteroneProgesterone, Micronized | 12 | $410 |
| Nebivolol Hcl | 11 | $360 |
| Spironolactone | 19 | $313 |
| Escitalopram Oxalate | 11 | $261 |
| Atorvastatin Calcium | 34 | $250 |
| Bupropion XlBupropion Hcl | 12 | $227 |
| Buspirone Hcl | 19 | $206 |
| Levothyroxine Sodium | 13 | $62 |
| Lisinopril | 12 | $41 |
| Alprazolam | 11 | $35 |
| Losartan Potassium | 15 | $24 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $12,817 | $51,75613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.
Other family in Atlanta
- Stacey TatroeAtlanta$38K
- Brandy HughesAtlanta$29K
- Cecile MartinAtlanta$23K
- Terri CowanAtlanta$21K
- Brandi Pinckney-GreeneAtlanta$18K
- Christopher VreelandAtlanta$17K
- Angelica MillerAtlanta$15K
- Andrea Jefferson SaboorAtlanta$14K
- Allie McAllisterMarietta$299K
- Erin HenryLawrenceville$135K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.